Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis

• Status: Not yet recruiting
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims at evaluating the therapeutic effects of both Nitazoxanide and Escitalopram as adjuvant therapies in patients with Rheumatoid Arthritis and to evaluate their impact on STAT3/ JAK2, TLR /IL -1β signaling pathways.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Citalopram; Nitazoxanide

Criteria

Inclusion Criteria:

• Diagnosed with rheumatoid arthritis according to the ACR/EULAR 2010 criteria.

• Receiving conventional disease modified anti rheumatic drugs (DMARDS).

• Having active disease (the 28-joint disease activity score [DAS28] according to the CRP formula > 2.6).

• Age between 18 and 75 years.

• Conscious and cooperative.

• Male or female.

• Sign an informed consent for the clinical study

Exclusion Criteria:

1. Pregnant or planning to be pregnant and breast-feeding women.

2. Chronic disease.

3. Other autoimmune diseases, such as systemic lupus erythematosus, Sjogren's syndrome and mixed connective tissue disease.

4. Patients treated with biological TNF-α, IL6 or IL-1β antagonists.

5. Infectious or inflammatory diseases, endocrine disorders, any past or current psychiatric or neurological diseases.

6. Clinically significant hepatic and renal dysfunction or impairment.

7. Alcohol abuse

8. Receiving therapy that interact with Nitazoxanide and Escitalopram.

9. Hypersensitivity to Nitazoxanide and Escitalopram.